<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652570</url>
  </required_header>
  <id_info>
    <org_study_id>119-01-01</org_study_id>
    <nct_id>NCT04652570</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy</brief_title>
  <official_title>A Phase 1b/2a Study of VB119 in Adult Subjects With Primary Membranous Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ValenzaBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ValenzaBio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1b/2a, open-label, sequential-cohort, dose escalation, and dose&#xD;
      expansion study to evaluate the safety, tolerability, PK, and PD of VB119 in subjects with&#xD;
      primary MN&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Through study completion, an average of 18 months</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Clinical Laboratory Assessments</measure>
    <time_frame>Through study completion, an average of 18 months</time_frame>
    <description>Safety and Tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of Patients with Anti-Drug Antibodies</measure>
    <time_frame>Through study completion, an average of 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration [Tmax]</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of patients achieving complete remission of proteinuria</measure>
    <time_frame>Through study completion, an average of 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PLA2R Antibody Assessment</measure>
    <time_frame>Through study completion, an average of 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as assessed by PROMIS</measure>
    <time_frame>Through study completion, an average of 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>VB119 dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation phase followed by a dose expansion phase. VB119 to be administered as intravenous infusions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VB119</intervention_name>
    <description>Humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb) to be administered as intravenous infusion at multiple timepoints during the study.</description>
    <arm_group_label>VB119 dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is ≥ 18 years of age at the time of informed consent;&#xD;
&#xD;
          2. Has a kidney biopsy-proven diagnosis of primary MN within the past 10 years; Note: It&#xD;
             is preferable that subjects enrolled have kidney biopsy tissue samples that are&#xD;
             positive for anti-PLA2R antibody staining. Subjects with kidney biopsy-proven&#xD;
             diagnosis of primary MN &gt;10 years and ≤20 years that meet all other eligibility&#xD;
             criteria may be enrolled after discussion with the Medical Monitor.&#xD;
&#xD;
          3. Has proteinuria with a UPCR ≥3.5 g/g, based on 2 consecutive 24-hour urine sample&#xD;
             collections obtained within 14 days of each other during the Screening Period. Both&#xD;
             samples must qualify;&#xD;
&#xD;
          4. Has systolic blood pressure (BP) &lt;160 mmHg or diastolic BP &lt;100 mmHg after 5 minutes&#xD;
             of rest at Screening;&#xD;
&#xD;
          5. Is willing and able to provide written informed consent prior to Screening;&#xD;
&#xD;
          6. Female subjects of non-childbearing potential must be either surgically sterile&#xD;
             (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy&#xD;
             at least 26 weeks before the Screening Visit) or postmenopausal, defined as&#xD;
             spontaneous amenorrhea for at least 2 years, with follicle-stimulating hormone in the&#xD;
             postmenopausal range at Screening, based on the central laboratory's ranges;&#xD;
&#xD;
          7. Female subjects of childbearing potential (ie, ovulating, premenopausal, or not&#xD;
             surgically sterile) and all male subjects must use a medically accepted, highly&#xD;
             effective contraceptive regimen during their participation in the study and for 125&#xD;
             days after the last administration of study drug.&#xD;
&#xD;
          8. Male subjects must agree to abstain from sperm donation through 125 days after&#xD;
             administration of the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has an eGFR &lt;30 mL/min/1.73 m2 at Screening utilizing the Chronic Kidney Disease&#xD;
             Epidemiology Collaboration formula confirmed by the central laboratory;&#xD;
&#xD;
          2. Has an absolute neutrophil count &lt;1.5 x 10/L;&#xD;
&#xD;
          3. Has a white blood cell count &lt;3.0 x 10/L;&#xD;
&#xD;
          4. Has secondary causes of MN (eg, malignancy, hepatitis B or C, human immunodeficiency&#xD;
             virus [HIV], systemic lupus erythematosus [SLE], or other autoimmune diseases [eg,&#xD;
             thyroiditis], drug-induced);&#xD;
&#xD;
          5. Has a diagnosis or history of SLE (including non renal disease);&#xD;
&#xD;
          6. Has type 1 diabetes mellitus;&#xD;
&#xD;
          7. Has an acute, chronic, or latent infection, including tuberculosis, hepatitis, HIV, or&#xD;
             chronic urinary tract infections;&#xD;
&#xD;
          8. Is positive for SARS-CoV-2 testing at Screening;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keenan</last_name>
    <role>Study Chair</role>
    <affiliation>ValenzaBio, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Project Director</last_name>
    <phone>(301) 755-9900</phone>
    <email>clinicaltrials@valenzabiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Granada Hills</city>
        <state>California</state>
        <zip>91344</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92691</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Vacaville</city>
        <state>California</state>
        <zip>95687</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Lewisville</city>
        <state>Texas</state>
        <zip>75057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Leicester</city>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W12 OHS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ValenzaBio Investigative Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

